Does IL-1 blockade with anakinra for 14 days reduce the incidence of new-onset heart failure or hospitalization for heart failure at 1 year in patients with STEMI?
A pooled analysis of the VCUART trials suggests that a 14-day course of anakinra following STEMI reduces the 1-year risk of new-onset heart failure or heart failure hospitalization.
IL-1 blockade with anakinra for 14 days in patients with STEMI reduces the incidence of new-onset HF or hospitalization for HF at 1 year following STEMI.
Abbate et al. (Thu,) studied this question.